Back to Search Start Over

Successful management of delayed-onset adenosine deaminase deficiency with novel mutation.

Authors :
Çelik FÇ
Soyöz Ö
Bölük SÖ
Taşkırdı İ
Hacı İA
Kaya MŞ
Demir A
Uzunoğlu B
Yıldırım AT
Onay H
Gözmen S
Gülez N
Genel F
Source :
Personalized medicine [Per Med] 2024 Jan; Vol. 21 (1), pp. 11-19. Date of Electronic Publication: 2023 Dec 13.
Publication Year :
2024

Abstract

A 4-year-old boy presented with acute-onset autoimmune cytopenia with severe, persistent lymphopenia, autoimmune thyroiditis, elevated IgE and glucose 6-phosphate dehydrogenase enzyme deficiency. In immunologic evaluation, lower T, B and natural killer cells and higher levels of adenosine deaminase (ADA) metabolites were observed. The compound heterozygous novel ADA gene mutations causing ADA deficiency were detected. Successful immunologic and metabolic cure was achieved with enzyme replacement therapy, followed by reduced intensity conditioning hematopoietic stem cell transplantation from a matched unrelated donor. An interesting aspect of this patient is the detection of novel compound heterozygous mutations without consanguinity and a secondary outcome is the recovery of glucose 6-phosphate dehydrogenase deficiency after hematopoietic stem cell transplantation.

Details

Language :
English
ISSN :
1744-828X
Volume :
21
Issue :
1
Database :
MEDLINE
Journal :
Personalized medicine
Publication Type :
Academic Journal
Accession number :
38088159
Full Text :
https://doi.org/10.2217/pme-2023-0111